Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$195.3MCash, Jun 2026
8moCash Runway (est.)
+21%Share Count, 1 Year
Follow REPL by emailGet an email when REPL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about REPL, unsubscribe in one click. Privacy
📣 What REPL Says Is Next
Q1 2027 · “Phase 2/3 transition is expected in Q1 2027.”
Company press release, Aug 14, 2026 · SEC filing
in 2030 · “The primary endpoint, expected to readout in 2030, is overall survival, and key secondary endpoints are progression free survival and overall response rate.”
Company press release, Aug 14, 2026 · SEC filing
Q1 2027 · “Phase 2/3 transition is expected in Q1 2027, with PFS analysis potentially supporting accelerated approval.”
Company press release, Feb 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
REPL reported $195.3M in cash and short-term investments (as of Jun 30, 2026) and used about $75.7M/quarter in operations, an estimated runway of 7.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:52 · Elevated
Cash runway 8 months +30
ATM program on file since May 2025 +15
Shelf registration (S-3ASR, Aug 2026) +10
Share count +21% in a year +7
Raised after last reported balance sheet (Aug 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REPL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.